Intervention: Nitroglycerin
Trial phase: Phase 2
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 229
Group description: Participants who received MED2005 (0.2% glyceryl trinitrate gel). At least 4 applications of MED2005 prior to intercourse in either the first or last 4 weeks of the study.
Eligibility criteria:
Inclusion Criteria:

Male aged between 18 and 70 years of age inclusive.
Confirmed self-diagnosis of ED for more than 3 months.
IIEF question 1 -5 and 15 score of 25 or less will be acceptable for inclusion to the run-in period.
Subject answers "yes" to the question "At home over the past 3 months, have you experienced at least some growth of your penis in response to: (1) mechanical stimulation, or (2) visual stimulation?"
In a continuous heterosexual relationship for at least 6 months prior to screening.
Documented written informed consent from both subject and his female partner.

Both partners must agree to use one of the acceptable methods of contraception listed below:

Occlusive cap (diaphragm or cervical/vault caps).
Surgical sterilisation (vasectomy with documentation of azoospermia).
The female partner uses oral contraceptives, injectable progesterone or subdermal implants.
The female partner uses medically prescribed topically-applied transdermal contraceptive patch.
The female partner has undergone documented tubal ligation (female sterilisation).
The female partner has undergone documented placement of an Intra Uterine Device (IUD).
Both partners are capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form.

Exclusion Criteria:

Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, psychiatric, or other disease.
Any history of an unstable medical or psychiatric condition or using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or delegate at screening.
Any presence of chronic indwelling urethral catheterization or penile anatomical abnormalities (e.g. penile fibrosis) that would significantly impair erectile function.
Any history of operations for Peyronie's disease.
Primary hypoactive sexual desire or any history of hypogonadism
Any history of radical prostatectomy.
Any history of severe / uncontrolled diabetes.
Subjects taking two or more anti-hypertensives for the treatment of blood pressure.
Subjects with nursing partners, known pregnant partners or wish to become pregnant during the course of the study.
Confirmed positive results from urine drug screen or from the alcohol breath test at screening and on admission (Day -1).
Subject has recent (last 12 months) clinical evidence of alcoholism or drug abuse.
Subject has a positive screen for hepatitis B consisting of Hepatitis B surface antigen (HBsAG), hepatitis C antibody, and human immunodeficiency virus (HIV).
Any clinically significant abnormal laboratory, vital signs or other safety findings at screening or on admission.
Subjects unwilling to cease use of vacuum devices, intracavernosal injection, Viagra ® or other therapy for ED.
Unwillingness of the subject to agree to make four attempts at sexual intercourse on four separate days during each treatment period.
Any history of unresponsiveness to Viagra ® treatment due to lack of efficacy with sexual stimulation after multiple attempts of sexual intercourse, or significant side effects excluding visual disturbances of Viagra ®.
Less than 4 attempts at sexual intercourse or high IIEF scores (> 25) during the run-in period.
Any known hypersensitivity to any component of the investigational product.
Subjects who are illiterate or are unable to understand the language in which the online questionnaires are available.
Subject has received any investigational product during the 90 days prior to dosing for this study.
Subject or their partner cannot communicate reliably with the Investigator.